Evidence map›Paper›PMID 40755684›Full record

ArticleCureus2025

Cholesterol, Cognition, and Controversy: A Case of Mood Disturbance on Repatha.

Matteo Conte, Boran Mao, Sara Tahir, Armando Rodriguez, Sayed T Hussain

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matteo ConteMedicine and Surgery, University of Padova, Padova, ITA.
Boran MaoInternal Medicine, University of Central Florida College of Medicine, Orlando, USA.
Sara TahirPhysiology, University of Florida, Gainesville, USA.
Armando RodriguezCardiology, Iberoamerican University School of Medicine, Santo Domingo, DOM.
Sayed T HussainInterventional Cardiology, University of Central Florida College of Medicine, Orlando, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 52-year-old woman with no prior psychiatric history who developed severe depressive symptoms shortly after starting evolocumab (Repatha) for lipid management. Her symptoms included persistent low mood and crying spells, which resolved completely after discontinuation of the medication. Her low-density lipoprotein (LDL)-cholesterol levels decreased significantly during this period. She was later switched to bempedoic acid and remained asymptomatic. This clinical course suggests a potential link between intensive LDL reduction and mood disturbances. While psychiatric side effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are rarely reported, this case raises awareness and underscores the need for mental health outcomes integration into future PCSK9 investigations.

Indexed as

adverse eventcardiovascularevolocumabmood disorderpcsk9

Identifiers

PMID40755684
PMCPMC12315930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.